Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.33 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | LATS1 | O95835 | 3/20 | 0.32 |
| ▸ | LATS2 | Q9NRM7 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26271984 | 0.84 | SIRT3 (0.36) | TRPA1SIRT3TDP1GAA | |
| SCHEMBL23508690 | 0.79 | LATS1 (0.33) | LATS1LATS2 | |
| SCHEMBL2737302 | 0.79 | RPS6KA3 (0.43) | TRPA1RPS6KA3SIRT3TDP1LATS1 | |
| SCHEMBL26272349 | 0.78 | HASPIN (0.32) | RPS6KA3 | |
| SCHEMBL26272345 | 0.78 | TP53 (0.34) | RPS6KA3 | |
| SCHEMBL10103687 | 0.78 | RPS6KA3 (0.41) | RPS6KA3LATS1LATS2 | |
| SCHEMBL13186489 | 0.78 | RPS6KA3 (0.41) | RPS6KA3LATS1LATS2 | |
| SCHEMBL13029049 | 0.75 | SIRT3 (0.38) | TRPA1RPS6KA3SIRT3TDP1LATS1 | |
| SCHEMBL2892375 | 0.75 | GAA (0.41) | TRPA1RPS6KA3SIRT3TDP1LATS1 | |
| SCHEMBL20693003 | 0.72 | TRPA1 (0.36) | TRPA1RPS6KA3SIRT3TDP1LATS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440666-B2 | Pyridazinone compounds and P2X7 receptor inhibitors | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-05-14 | — | — | US | disclosed |
| US-20100286390-A1 | PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS | NISSAN CHEMICAL INDUSTRIES LIMITED | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286390-A1 | PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS | P2RY1, P2RX7, P2RX1 | TRPA1 64/4885RPS6KA3 1965/4885SIRT3 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.